These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 1728830)

  • 1. Preclinical pharmacology of fluoxetine, a serotonergic drug for weight loss.
    Yen TT; Fuller RW
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):177S-180S. PubMed ID: 1728830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appraisal of the clinical value of serotoninergic drugs.
    Munro JF; Scott C; Hodge J
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):189S-192S. PubMed ID: 1728833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress report on the anorectic effects of dexfenfluramine, fluoxetine and sertraline.
    Garattini S; Bizzi A; Caccia S; Mennini T
    Int J Obes Relat Metab Disord; 1992 Dec; 16 Suppl 3():S43-50. PubMed ID: 1338321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hyperphagia and weight loss during fluoxetine treatment.
    Fichtner CG; Braun BG
    Ann Pharmacother; 1994 Dec; 28(12):1350-2. PubMed ID: 7696724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice.
    Nielsen JA; Chapin DS; Johnson JL; Torgersen LK
    Am J Clin Nutr; 1992 Jan; 55(1 Suppl):185S-189S. PubMed ID: 1728832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dexfenfluramine, fluoxetine, and weight loss among female carbohydrate cravers.
    Wurtman J; Wurtman R; Berry E; Gleason R; Goldberg H; McDermott J; Kahne M; Tsay R
    Neuropsychopharmacology; 1993 Nov; 9(3):201-10. PubMed ID: 8280344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub).
    Levine LR; Enas GG; Thompson WL; Byyny RL; Dauer AD; Kirby RW; Kreindler TG; Levy B; Lucas CP; McIlwain HH
    Int J Obes; 1989; 13(5):635-45. PubMed ID: 2583918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined naloxone and fluoxetine on deprivation-induced binge eating of palatable foods in rats.
    Hagan MM; Holguin FD; Cabello CE; Hanscom DR; Moss DE
    Pharmacol Biochem Behav; 1997 Dec; 58(4):1103-7. PubMed ID: 9408220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An investigation of tolerance to the actions of leptogenic and anorexigenic drugs in mice.
    Morley JE; Flood JF
    Life Sci; 1987 Nov; 41(18):2157-65. PubMed ID: 2890074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoxetine increases the anorectic and long-term dopamine-depleting effects of phentermine.
    Callahan BT; Yuan J; Ricaurte GA
    Synapse; 2000 Dec; 38(4):471-6. PubMed ID: 11044894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5-HT(1A) activation counteracts cardiovascular but not hypophagic effects of sibutramine in rats.
    Thomas GH; Babbs AJ; Chatfield RE; Krülle TM; Widdowson PS; Provost D; McCormack JG
    Obesity (Silver Spring); 2009 Mar; 17(3):467-73. PubMed ID: 19219064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine.
    Dryden S; Brown M; King P; Williams G
    Horm Metab Res; 1999 Jun; 31(6):363-6. PubMed ID: 10437624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoxetine effects on serotonin function and aggressive behavior.
    Fuller RW
    Ann N Y Acad Sci; 1996 Sep; 794():90-7. PubMed ID: 8853595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial reversal of fluoxetine anorexia by the 5-HT antagonist metergoline.
    Lee MD; Clifton PG
    Psychopharmacology (Berl); 1992; 107(2-3):359-64. PubMed ID: 1615137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents.
    Heal DJ; Cheetham SC; Prow MR; Martin KF; Buckett WR
    Br J Pharmacol; 1998 Sep; 125(2):301-8. PubMed ID: 9786502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biological actions of drugs affecting serotonin and eating.
    Garattini S
    Obes Res; 1995 Nov; 3 Suppl 4():463S-470S. PubMed ID: 8697044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily high doses of fluoxetine for weight loss and improvement in lifestyle before bariatric surgery.
    Dolfing JG; Wolffenbuttel BH; ten Hoor-Aukema NM; Schweitzer DH
    Obes Surg; 2005 Sep; 15(8):1185-91. PubMed ID: 16197794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D1 and D2 antagonists reverse the effects of appetite suppressants on weight loss, food intake, locomotion, and rebalance spiking inhibition in the rat NAc shell.
    Kalyanasundar B; Perez CI; Luna A; Solorio J; Moreno MG; Elias D; Simon SA; Gutierrez R
    J Neurophysiol; 2015 Jul; 114(1):585-607. PubMed ID: 25972577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice.
    Dubuc PU; Peterson CM
    J Pharmacol Exp Ther; 1990 Dec; 255(3):976-9. PubMed ID: 2124625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss.
    Esler WP; Rudolph J; Claus TH; Tang W; Barucci N; Brown SE; Bullock W; Daly M; Decarr L; Li Y; Milardo L; Molstad D; Zhu J; Gardell SJ; Livingston JN; Sweet LJ
    Endocrinology; 2007 Nov; 148(11):5175-85. PubMed ID: 17656463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.